We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi

Alexander CJ van Akkooi MD, PhD

Melanoma and Soft Tissue Sarcoma Surgeon, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in melanoma and sarcoma and practicing at the Netherlands Cancer Institute – Antoni van Leeuwenhoek (NCI-AVL) in Amsterdam. Dr van Akkooi is the current chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. He is the head of the NCI-AVL Skin Cancer and Melanoma Unit. Dr van Akkooi has published over 150 peer-reviewed papers in high-impact journals, including NEJM, Lancet, Lancet Oncology, Cell, Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology, Society for Melanoma Research, and American Society of Clinical Oncology.

Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam, and underwent residency training in surgical oncology at NCI-AVL and Erasmus MC Cancer Institute. His PhD was awarded cum laude from Erasmus University.

Disclosures

Dr. van Akkooi is on the Advisory Board of & has received Consultancy Honoraria from Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Sanofi, 4SC. He also reports Research Grants from Amgen, Novartis, Merck-Pfizer which were all paid to NCI-AVL.

Recent Contributions to PracticeUpdate:

  1. Long-Term Outcomes With Dabrafenib Plus Trametinib in BRAF V600-Mutant Melanoma
  2. Overview of Melanoma Studies at ASCO
  3. Real-World Outcomes of Targeted Therapies and Immunotherapy for Metastatic Melanoma
  4. Practice-Changing Developments in Stage III Melanoma
  5. Prognostic Variables in Stage III Melanoma
  6. ESMO 2018: Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma
  7. ESMO 2018: T-VEC in Early Metastatic Melanoma
  8. Adjuvant Therapy for Resected Stage III Melanoma
  9. ASCO 2018: A Review of Current and Upcoming Data on Neoadjuvant Immunotherapy for Melanoma
  10. ASCO 2018: Implications for the Clinician of the New AJCC Staging System for Melanoma

Most Read This Week

Recently Updated